PTC Therapeutics muscular disorder drug turned down by EU

Posted: Published on January 25th, 2014

This post was added by Dr Simmons

January 24, 2014 7:54 am by Staff | 0 Comments MedCity News

(Reuters) - PTC Therapeutics Inc said a committee of the European Medicines Agency did not recommend conditional approval of its drug for the treatment of a rare muscular disorder, sending its shares down as much as 28 percent in premarket trading.

The company said it intends to request the committee for a re-examination. It was seeking a so-called conditional approval, granted to treatments that show early benefit. The drugmaker still needs to conduct trials.

The drug, ataluren, is intended to treat a form of Duchenne muscular dystrophy which occurs due to a type of genetic mutation known as a nonsense mutation.

PTC Therapeutics joins a list of companies struggling with regulatory setbacks to their Duchenne muscular dystrophy drug programs. Sarepta Therapeutics Inc and Prosensa Holding NV recently faced U.S. regulatory setbacks.

PTC Therapeutics shares closed at $26.22 on Thursday on the Nasdaq.

Get our daily newsletter or follow us.

Please enter your email below:

Read more from the original source:
PTC Therapeutics muscular disorder drug turned down by EU

Related Posts
This entry was posted in Muscular Dystrophy Treatment. Bookmark the permalink.

Comments are closed.